J&J Acquires Numab's Eczema Drug in $1.25B Deal
TL;DR Summary
Johnson & Johnson is acquiring Yellow Jersey Therapeutics from Numab Therapeutics for $1.25 billion in cash, marking its second acquisition in the immunology and inflammation (I&I) sector.
Topics:business#acquisition#dealspharma#dollar125-billion#johnson-and-johnson#numab-therapeutics#yellow-jersey
- J&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey Endpoints News
- J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal Fierce Biotech
- J&J Acquires Experimental Eczema Drug in $1.25 Billion Cash Deal Bloomberg
- J&J to buy Yellow Jersey for over $1B (NYSE:JNJ) Seeking Alpha
- J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Bln Deal MarketWatch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
65%
77 → 27 words
Want the full story? Read the original article
Read on Endpoints News